Douglas W. Blayney

Publications

• Measuring the improving quality of outpatient care in medical oncology practices in the United States. Neuss MN, Malin JL, Chan S, Kadlubek PJ, Adams JL, Jacobson JO, Blayney DW, Simone JV. J Clin Oncol. 2013; 31 (11): 1471-7
• Tumor boards (team huddles) aren't enough to reach the goal. Blayney DW, J Natl Cancer Inst. 2013; 105 (2): 82-4
• Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC. J Clin Oncol. 2012; 30 (18): 2218-26
• American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS. J Clin Oncol. 2012; 30 (14): 1715-24
• Michigan oncology practices showed varying adherence rates to practice guidelines, but quality interventions improved care. Blayney DW, Severson J, Martin CJ, Kadlubek P, Ruane T, Harrison K. Health Aff (Millwood). 2012; 31 (4): 718-28
• Enhancing quality through innovation: American Society of Clinical Oncology presidential address 2010. Blayney DW, J Clin Oncol. 2010; 28 (28): 4283-8
• Implementation of the Quality Oncology Practice Initiative at a university comprehensive cancer center. Blayney DW, McNiff K, Hanauer D, Miela G, Markstrom D, Neuss M. J Clin Oncol. 2009; 27 (23): 3802-7
• Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH. Oncologist. 2005; 10 (2): 138-49
• Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Cancer. 2012; 118 (22): 5463-72
• Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Blood. 2012; 119 (9): 2093-9
• The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. Kleinman L, Benjamin K, Viswanathan H, Mattera MS, Bosserman L, Blayney DW, Revicki DA. Qual Life Res. 2012; 21 (7): 1255-66
• The effect of age on delay in diagnosis and stage of breast cancer. Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Oncologist. 2012; 17 (6): 775-82
• Time to diagnosis and breast cancer stage by race/ethnicity. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Breast Cancer Res Treat. 2012; 136 (3): 813-21
• Commentary: six years of trends in oncology practice data. Blayney DW, J Oncol Pract. 2011; 7 (5): 291-3
• Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence? Wong YN, Ottesen RA, Hughes ME, Niland JC, Theriault R, Edge SB, Blayney D, Weeks JC. Oncologist. 2011; 16 (5): 559-65
• Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Greenberg CC, Lipsitz SR, Hughes ME, Edge SB, Theriault R, Wilson JL, Carter WB, Blayney DW, Niland J, Weeks JC. Ann Surg. 2011; 254 (2): 339-45
• Myeloid growth factors. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. J Natl Compr Canc Netw. 2011; 9 (8): 914-32
• The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers. Brewster AM, Etzel C, Zhou R, Wong Y, Edge S, Blayney DW, Wilson J, Hudis C, Ottesen R, Hughes ME, Weeks JC, Theriault RL. Breast Cancer Res Treat. 2011; 130 (3): 897-904
• Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. Baer AR, Kelly CA, Bruinooge SS, Runowicz CD, Blayney DW. J Oncol Pract. 2010; 6 (3): 114-7
• Expansion of cancer care and control in countries of low and middle income: a call to action. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR. Lancet. 2010; 376 (9747): 1186-93
• Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. J Clin Oncol. 2009; 27 (20): 3354-62
• Partnering with payers for success: quality oncology practice initiative, blue cross blue shield of michigan, and the michigan oncology quality consortium. Blayney DW, Stella PJ, Ruane T, Martin J, Lavasseur B, Leyden T, Malloy M. J Oncol Pract. 2009; 5 (6): 281-4
• Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. J Clin Oncol. 2008; 26 (34): 5553-60
• The registry case finding engine: an automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes. Hanauer DA, Miela G, Chinnaiyan AM, Chang AE, Blayney DW. J Am Coll Surg. 2007; 205 (5): 690-7
• Defining Quality: QOPI Is a Start. Blayney DW, J Oncol Pract. 2006; 2 (5): 203
• Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. J Clin Oncol. 2003; 21 (13): 2466-73
• Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. Blayney DW, Longo DL, Young RC, Greene MH, Hubbard SM, Postal MG, Duffey PL, DeVita VT. N Engl J Med. 1987; 316 (12): 710-4
• The human T-cell leukemia-lymphoma virus in the southeastern United States. Blayney DW, Blattner WA, Robert-Guroff M, Jaffe ES, Fisher RI, Bunn PA, Patton MG, Rarick HR, Gallo RC. JAMA. 1983; 250 (8): 1048-52
• The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma. Blayney DW, Jaffe ES, Blattner WA, Cossman J, Robert-Guroff M, Longo DL, Bunn PA, Gallo RC. Blood. 1983; 62 (2): 401-5
• The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia. Blayney DW, Jaffe ES, Fisher RI, Schechter GP, Cossman J, Robert-Guroff M, Kalyanaraman VS, Blattner WA, Gallo RC. Ann Intern Med. 1983; 98 (2): 144-51